Pemphigus Vulgaris Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Pemphigus vulgaris is a rare autoimmune disease that causes painful blistering on the skin and the mucous membranes. Risk factors include race, gender and age. Symptoms of pemphigus vulgaris include painful blisters that start in the mouth, skin blisters that come and go; the blisters always occur near the surface of the skin and oozing, crusting, or peeling at the blister site.
The Pemphigus Vulgaris pipeline drugs market research report provides a comprehensive information on the therapeutics under development for Pemphigus Vulgaris, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects.
Pemphigus Vulgaris Pipeline Drugs Market Segmentation by Targets
The key targets in the Pemphigus Vulgaris pipeline drugs market are Cells Expressing B Lymphocyte Antigen CD20, IgG Receptor FcRn Large Subunit p51, Tyrosine Protein Kinase BTK, Cells Expressing Desmoglein 1, Cells Expressing Desmoglein 3, Low Density Lipoprotein Receptor Related Protein, Toll Like Receptor 2, and Tyrosine Protein Kinase JAK3.
Pemphigus Vulgaris Pipeline Drugs Market Analysis, by Targets
For more insights on Pemphigus Vulgaris pipeline drugs targets, download a free report sample
Pemphigus Vulgaris Pipeline Drugs Market Segmentation by Mechanism of Actions
The key mechanism of actions in the Pemphigus Vulgaris pipeline drugs market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, IgG Receptor FcRn Large Subunit p51 Antagonist, Tyrosine Protein Kinase BTK Inhibitor, Cytotoxic To Cells Expressing Desmoglein 1, Cytotoxic To Cells Expressing Desmoglein 3, Low Density Lipoprotein Receptor Related Protein Agonist, Toll Like Receptor 2 Agonist, and Tyrosine Protein Kinase JAK3 Inhibitor.
Pemphigus Vulgaris Pipeline Drugs Market Analysis, by Mechanism of Actions
For more insights on Pemphigus Vulgaris pipeline drugs mechanism of actions, download a free report sample
Pemphigus Vulgaris Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Pemphigus Vulgaris pipeline drugs market are intravenous, subcutaneous, and oral.
Pemphigus Vulgaris Pipeline Drugs Market Analysis, by Routes of Administration
For more insights on Pemphigus Vulgaris pipeline drugs routes of administration, download a free report sample
Pemphigus Vulgaris Pipeline Drugs Market Segmentation by Key Molecule Types
The key molecule types in the Pemphigus Vulgaris pipeline drugs market are monoclonal antibody, small molecule, gene-modified cell therapy, peptide, cell therapy, and recombinant protein.
Pemphigus Vulgaris Pipeline Drugs Market Analysis, by Molecule Types
For more insights on Pemphigus Vulgaris pipeline drugs molecule type, download a free report sample
Competitive Landscape
Some of the leading companies in the Pemphigus Vulgaris pipeline drugs market are Cabaletta Bio Inc, HanAll Biopharma Co Ltd, Argenx SE, BioXpress Therapeutics SA, Daewoong Pharmaceutical Co Ltd, Evopoint Bioscience Co Ltd, iBio Inc, ImmunoWork LLC, Octagon Therapeutics Inc, and Pharmapraxis among others.
Pemphigus Vulgaris Pipeline Drugs Market Analysis, by Companies
To know more about the leading players in the Pemphigus Vulgaris pipeline drugs market, download a free report sample
Pemphigus Vulgaris Pipeline Drugs Market Overview
| Key Targets | Cells Expressing B Lymphocyte Antigen CD20, IgG Receptor FcRn Large Subunit p51, Tyrosine Protein Kinase BTK, Cells Expressing Desmoglein 1, Cells Expressing Desmoglein 3, Low Density Lipoprotein Receptor Related Protein, Toll Like Receptor 2, and Tyrosine Protein Kinase JAK3 |
| Key Mechanism of Actions | Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, IgG Receptor FcRn Large Subunit p51 Antagonist, Tyrosine Protein Kinase BTK Inhibitor, Cytotoxic To Cells Expressing Desmoglein 1, Cytotoxic To Cells Expressing Desmoglein 3, Low Density Lipoprotein Receptor Related Protein Agonist, Toll Like Receptor 2 Agonist, and Tyrosine Protein Kinase JAK3 Inhibitor |
| Key Routes of Administration | Intravenous, Subcutaneous, and Oral |
| Key Molecule Types | Monoclonal Antibody, Small Molecule, Gene-Modified Cell Therapy, Peptide, Cell Therapy, and Recombinant Protein |
| Leading Companies | Cabaletta Bio Inc, HanAll Biopharma Co Ltd, Argenx SE, BioXpress Therapeutics SA, Daewoong Pharmaceutical Co Ltd, Evopoint Bioscience Co Ltd, iBio Inc, ImmunoWork LLC, Octagon Therapeutics Inc, and Pharmapraxis |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pemphigus Vulgaris (Immunology).
- The pipeline guide reviews pipeline therapeutics for Pemphigus Vulgaris (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pemphigus Vulgaris (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pemphigus Vulgaris (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pemphigus Vulgaris (Immunology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pemphigus Vulgaris (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pemphigus Vulgaris (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
BioXpress Therapeutics SA
Cabaletta Bio Inc
Daewoong Pharmaceutical Co Ltd
Evopoint Bioscience Co Ltd
HanAll Biopharma Co Ltd
iBio Inc
ImmunoWork LLC
Octagon Therapeutics Inc
Pharmapraxis
Serpin Pharma LLC
Topas Therapeutics GmbH
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Pemphigus Vulgaris pipeline drugs market?
The key targets in the Pemphigus Vulgaris pipeline drugs market are Cells Expressing B Lymphocyte Antigen CD20, IgG Receptor FcRn Large Subunit p51, Tyrosine Protein Kinase BTK, Cells Expressing Desmoglein 1, Cells Expressing Desmoglein 3, Low Density Lipoprotein Receptor Related Protein, Toll Like Receptor 2, and Tyrosine Protein Kinase JAK3.
-
What are the key mechanism of actions in the Pemphigus Vulgaris pipeline drugs market?
The key mechanism of actions in the Pemphigus Vulgaris pipeline drugs market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, IgG Receptor FcRn Large Subunit p51 Antagonist, Tyrosine Protein Kinase BTK Inhibitor, Cytotoxic To Cells Expressing Desmoglein 1, Cytotoxic To Cells Expressing Desmoglein 3, Low Density Lipoprotein Receptor Related Protein Agonist, Toll Like Receptor 2 Agonist, and Tyrosine Protein Kinase JAK3 Inhibitor.
-
What are the key routes of administration in the Pemphigus Vulgaris pipeline drugs market?
The key routes of administration in the Pemphigus Vulgaris pipeline drugs market are intravenous, subcutaneous, and oral.
-
What are the key molecule types in the Pemphigus Vulgaris pipeline drugs market?
The key molecule types in the Pemphigus Vulgaris pipeline drugs market are monoclonal antibody, small molecule, gene-modified cell therapy, peptide, cell therapy, and recombinant protein.
-
Which are the leading companies in the Pemphigus Vulgaris pipeline drugs market?
The leading companies in the Pemphigus Vulgaris pipeline drugs market are Cabaletta Bio Inc, HanAll Biopharma Co Ltd, Argenx SE, BioXpress Therapeutics SA, Daewoong Pharmaceutical Co Ltd, Evopoint Bioscience Co Ltd, iBio Inc, ImmunoWork LLC, Octagon Therapeutics Inc, and Pharmapraxis.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Pemphigus Vulgaris Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Immunology reports